Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x100px

Document › Details

Affimed N.V.. (5/22/19). "Press Release: Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio, Reports First Quarter 2019 Financial Results and Operational Progress". Heidelberg.

	Organisation	Affimed N.V. (Nasdaq: AFMD)
	Group	Affimed (Group)
	Organisation 2	Genentech Inc.
	Group	Roche (Group)
	Product	AFM11 (Affimed)
	Product 2	AFM13 (Affimed)
	Person	Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
	Person 2	Gin, Gregory (Affimed 201808 Head of Investor Relations)

Original document
accessed by [iito] on 2019-05-29

Record changed: 2023-06-05

Picture Berlin Partner Top News CareSyntax Raises $61m for Bio Cheese 650x200px

More documents for Affimed (Group)

[1] Affimed N.V.. (3/6/24). "Press Release: Affimed Announces 1-for-10 Reverse Stock Split". Mannheim....
[2] Affimed N.V.. (1/3/24). "Press Release: Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck". Mannheim....
[3] Affimed N.V.. (11/3/22). "Press Release: Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101". Heidelberg & San Diego, CA....
[4] Affimed N.V.. (11/1/22). "Press Release: Affimed to Present at the 2022 Jefferies London Healthcare Conference". Heidelberg....
[5] Affimed N.V.. (9/1/22). "Press Release: Affimed to Present at Upcoming Investor Conferences". Heidelberg....
[6] Affimed N.V.. (4/13/22). "Press Release: Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares". Heidelberg....
[7] Affimed N.V.. (4/12/22). "Press Release: Affimed Announces Proposed Public Offering of Common Shares". Heidelberg....
[8] Affimed N.V.. (4/10/22). "Press Release: Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting". Heidelberg....
[9] Affimed N.V.. (4/8/22). "Press Release: Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of AFM24 in Patients with EGFR-positive Solid Tumors". Heidelberg....
[10] Affimed N.V.. (3/31/22). "Press Release: Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress". Heidelberg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]